Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
63 hedge funds and large institutions have $148M invested in Aptose Biosciences, Inc. in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 17 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 16
10% less funds holding
Funds holding: 70 → 63 (-7)
13% less call options, than puts
Call options by funds: $447K | Put options by funds: $516K
41% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 17
53% less capital invested
Capital invested by funds: $313M → $148M (-$165M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$7.7M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$4.9M |
| 3 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$4.45M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$3.63M |
| 5 |
DS
DRW Securities
Chicago,
Illinois
|
+$2.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$16.1M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$9.6M |
| 3 |
VA
VR Adviser
New York
|
-$9.59M |
| 4 |
ABG
Ally Bridge Group
New York
|
-$8.42M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$4.16M |
APTO Hedge Fund Activity: Q2 2021 in Review
63 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q2 2021, worth a combined $148M — down 53% from $313M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of APTO and 10 opened new positions — a net loss of 7 holders — while 16 trimmed existing stakes and 18 added.
The largest buyer was 683 Capital Management, adding an estimated $7.7M. The largest seller was Pictet Asset Management (UK), exiting entirely with an estimated $16.1M sold.
- 63 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q2 2021, down from 70 in Q1 2021.
- Funds reported $148M of Aptose Biosciences, Inc. stock for Q2 2021, down 53% quarter-over-quarter.
- 10 funds opened new Aptose Biosciences, Inc. positions in Q2 2021 and 17 closed out, a net change of -7 holders.
- The largest Aptose Biosciences, Inc. buyer in Q2 2021 was 683 Capital Management, an estimated $7.7M added.
- The largest Aptose Biosciences, Inc. seller in Q2 2021 was Pictet Asset Management (UK), an estimated $16.1M sold.
Based on aggregated 13F filings for Q2 2021.